Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNYSE:ENOVNASDAQ:LMATNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.53+0.3%$7.79$5.28▼$14.38$536.40M0.95455,886 shs587,066 shsENOVEnovis$31.61-2.3%$34.73$29.32▼$51.00$1.81B1.79786,005 shs692,977 shsLMATLeMaitre Vascular$81.40+2.9%$84.26$71.42▼$109.58$1.84B0.86166,624 shs205,755 shsNVCRNovoCure$18.54+2.4%$17.53$14.17▼$34.13$2.07B0.731.14 million shs869,910 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+0.15%-0.46%-13.08%-34.97%+3.33%ENOVEnovis-0.17%-9.77%-0.76%-24.34%-36.61%LMATLeMaitre Vascular-2.92%-5.02%-8.16%-20.58%-1.12%NVCRNovoCure+2.03%+2.96%+9.69%-18.02%-23.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.0784 of 5 stars3.30.00.00.02.44.21.3ENOVEnovis3.2627 of 5 stars3.42.00.00.04.21.71.9LMATLeMaitre Vascular2.5806 of 5 stars2.32.03.30.01.92.51.3NVCRNovoCure3.5948 of 5 stars3.31.00.04.53.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$14.33119.50% UpsideENOVEnovis 2.80Moderate Buy$58.0083.48% UpsideLMATLeMaitre Vascular 2.63Moderate Buy$98.1420.57% UpsideNVCRNovoCure 2.67Moderate Buy$32.8377.09% UpsideCurrent Analyst Ratings BreakdownLatest BVS, ENOV, NVCR, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.004/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.004/2/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.003/17/2025BVSBioventusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/28/2025LMATLeMaitre VascularLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$105.00 ➝ $110.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.94$0.52 per share12.58$2.80 per share2.33ENOVEnovis$2.15B0.84$4.61 per share6.86$62.66 per share0.50LMATLeMaitre Vascular$226.26M8.13$1.44 per share56.52$13.38 per share6.08NVCRNovoCure$621.71M3.32N/AN/A$3.39 per share5.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.20N/A-7.11%15.61%4.01%N/AENOVEnovis-$33.26M-$13.95N/A9.91N/A-5.95%4.39%2.80%8/6/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9844.4837.512.2219.40%13.15%11.47%8/7/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)Latest BVS, ENOV, NVCR, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million2/27/2025Q4 2024LMATLeMaitre Vascular$0.49$0.49N/A$0.49$55.99 million$55.81 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/26/2025Q4 2024ENOVEnovis$0.92$0.98+$0.06-$12.05$555.14 million$560.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.98%+13.30%40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest BVS, ENOV, NVCR, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99ENOVEnovis0.402.271.12LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%ENOVEnovis98.45%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipBVSBioventus32.90%ENOVEnovis2.70%LMATLeMaitre Vascular9.50%NVCRNovoCure6.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableENOVEnovis6,80057.12 million55.49 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableBVS, ENOV, NVCR, and LMAT HeadlinesRecent News About These CompaniesNovoCure Limited (NASDAQ:NVCR) Holdings Boosted by Millennium Management LLCMay 23 at 4:09 AM | marketbeat.comNovoCure Limited: Profitability Remains ElusiveMay 21 at 6:43 PM | seekingalpha.comSoleus Capital Management L.P. Takes Position in NovoCure Limited (NASDAQ:NVCR)May 21 at 8:13 AM | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AGMay 21 at 3:52 AM | marketbeat.comTeza Capital Management LLC Purchases 85,312 Shares of NovoCure Limited (NASDAQ:NVCR)May 20 at 7:40 AM | marketbeat.comSilvercrest Asset Management Group LLC Decreases Stock Position in NovoCure Limited (NASDAQ:NVCR)May 20 at 5:46 AM | marketbeat.comQuantinno Capital Management LP Acquires 43,108 Shares of NovoCure Limited (NASDAQ:NVCR)May 18, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Graham Capital Management L.P.May 17, 2025 | marketbeat.comLMR Partners LLP Buys Shares of 32,914 NovoCure Limited (NASDAQ:NVCR)May 16, 2025 | marketbeat.comDoes NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?May 15, 2025 | zacks.comNovoCure Limited (NASDAQ:NVCR) Receives $32.83 Average Price Target from AnalystsMay 13, 2025 | americanbankingnews.comNorthern Trust Corp Boosts Holdings in NovoCure Limited (NASDAQ:NVCR)May 12, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Average Rating of "Moderate Buy" by AnalystsMay 12, 2025 | marketbeat.comFrontier Capital Management Co. LLC Sells 145,096 Shares of NovoCure Limited (NASDAQ:NVCR)May 11, 2025 | marketbeat.comAlgert Global LLC Buys Shares of 69,261 NovoCure Limited (NASDAQ:NVCR)May 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Reduces Stock Position in NovoCure Limited (NASDAQ:NVCR)May 11, 2025 | marketbeat.comCubist Systematic Strategies LLC Increases Position in NovoCure Limited (NASDAQ:NVCR)May 10, 2025 | marketbeat.comBalyasny Asset Management L.P. Grows Stock Holdings in NovoCure Limited (NASDAQ:NVCR)May 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)May 6, 2025 | marketbeat.comPDT Partners LLC Trims Holdings in NovoCure Limited (NASDAQ:NVCR)May 2, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Price T Rowe Associates Inc. MDMay 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?BVS, ENOV, NVCR, and LMAT Company DescriptionsBioventus NYSE:BVS$6.53 +0.02 (+0.31%) Closing price 04:00 PM EasternExtended Trading$6.35 -0.18 (-2.74%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Enovis NYSE:ENOV$31.61 -0.76 (-2.34%) Closing price 03:59 PM EasternExtended Trading$31.56 -0.06 (-0.18%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$81.40 +2.28 (+2.88%) Closing price 04:00 PM EasternExtended Trading$81.47 +0.07 (+0.09%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$18.54 +0.43 (+2.37%) Closing price 04:00 PM EasternExtended Trading$18.48 -0.05 (-0.30%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
